Childhood Kidney Diseases

Korean Society of Pediatric Nephrology (대한소아신장학회)
권호 표지
DOI QR코드

DOI QR Code

Slowing the Progression of Chronic Kidney Disease in Children and Adolescents

소아 청소년 만성 콩팥병의 진행 억제

  • Ha, Il-Soo (Department of Pediatrics, Seoul National University Children's Hospital Kidney Institute, Seoul National University Medical Research Center) ;
  • Choi, Yong (Department of Pediatrics, Inje University Haeundae Paik Hospital)
  • 하일수 (서울대학교 어린이병원 소아청소년과, 서울대학교 의과대학 의학연구원 신장연구소) ;
  • 최용 (인제대학교 해운대백병원 소아청소년과)
  • Received : 2010.04.05
  • Accepted : 2010.04.20
  • Published : 2010.04.30
Download PDF
⟨ Previous Next ⟩

Abstract

Slowing the progression of chronic kidney disease is much more important in children and adolescents with a relatively longer remaining life span. A practical way to assess the rate of progression of chronic kidney disease is to measure the change of GFR estimated by formulae. To slow the progression, hypertension and proteinuria have to be controlled strictly, and hypoplastic anemia must be treated with erythropoietin. If not contraindicated, ACE inhibitor or angiotensin receptor blocker is recommended with monitoring of the side effects. Trials to slow the progression should be commenced as soon as the chronic kidney disease is confirmed and needs to be continued until renal transplantation as long as residual renal function remains. An online system, the Korean Pediatric Chronic Kidney Disease Registry (http://pedcrf.or.kr/), provides tools that are useful in evaluation and management of the children and adolescents with chronic kidney diseases.

긴 잔여 수명을 가진 소아-청소년기에 발생한 만성 콩팥병의 진행을 억제하는 것은 매우 중요하다. 콩팥 기능의 변화는 공식을 이용하여 혈청 크레아틴이나 시스타틴 C 치를 이용한 사구체 여과율의 추정치를 계산하는 것이 비교적 정확하고 편리하다. 고혈압과 단백뇨는 엄격하게 조절되어야 하며 빈혈은 에리트로포이에틴으로 교정되어야 한다. 혈압이 정상인 경우에도 특별한 금기사항이 없는 한 ACE 억제제나 안지오텐신 수용체 차단제를 사용하는 것이 필요하나 부작용의 발생에 주의할 필요가 있다. 만성 콩팥병의 진행 억제를 위한 노력은 만성 콩팥병이 확인되는 대로 가능한 일찍 시작되어야 하며 콩팥 이식을 받을 때까지 잔여 신기능이 남아 있는 한 계속되어야 한다. 온라인 한국 소아 만성 콩팥병 등록 시스템이 만성 콩팥병의 진료에 도움을 준다.

Keywords

References

  1. Mitsnefes M, Ho PL, McEnery PT. Hypertension and progression of chronic renal insufficiency in children: a report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS). J Am Soc Nephrol 2003;14:2618-22. https://doi.org/10.1097/01.ASN.0000089565.04535.4B
  2. Litwin, M. Risk factors for renal failure in children with non-glomerular nephropathies. Pediatr Nephrol 2004;19:178-86. https://doi.org/10.1007/s00467-003-1329-4
  3. Furth SL, Cole SR, Fadrowski JJ, Gerson A, Pierce CB, Chandra M, et al. The association of anemia and hypoalbuminemia with accelerated decline in GFR among adolescents with chronic kidney disease. Pediatr Nephrol 2007;22:265-71.
  4. Soares CM, Diniz JS, Lima EM, Oliveira GR, Canhestro MR, Colosimo EA, et al. Predictive factors of progression to chronic kidney disease stage 5 in a predialysis interdisciplinary programme. Nephrol Dial Transplant 2009;24:848-55.
  5. Wuhl E, Trivelli A, Picca S, Litwin M, Peco-Antic A, Zurowska A, et al. Strict blood pressure control and progression of renal failure in children. N Engl J Med 2009;361: 1639-50. https://doi.org/10.1056/NEJMoa0902066
  6. NKF. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002;39(Suppl 1):S1-266.
  7. Schwartz GJ, Haycock GB, Edelmann CM, Spitzer A. A simple estimate of glomerular filtration rate in children derived from body length and plasma creatinine. Pediatrics 1976;58:259-63.
  8. Counahan R, Chantler C, Ghazali S, Kirkwood B, Rose F, Barratt TM. Estimation of glomerular filtration rate from plasma creatinine concentration in children. Arch Dis Child 1976;51:875-8. https://doi.org/10.1136/adc.51.11.875
  9. Filler G, Lepage N. Should the Schwartz formula for estimation of GFR be replaced by cystatin C formula? Pediatr Nephrol 2003;18:981-5. https://doi.org/10.1007/s00467-003-1271-5
  10. Bouvet Y, Bouissou F, Coulais Y, Seronie-Vivien S, Tafani M, Decramer S, et al. GFR is better estimated by considering both serum cystatin C and creatinine levels. Pediatr Nephrol 2006;21:1299-306. https://doi.org/10.1007/s00467-006-0145-z
  11. Zappitelli M, Parvex P, Joseph L, Paradis G, Grey V, Lau S, et al. Derivation and validation of cystatin C-based prediction equations for GFR in children. Am J Kidney Dis 2006;48:221-30. https://doi.org/10.1053/j.ajkd.2006.04.085
  12. Schwartz GJ, Munoz A, Schneider MF, Mak RH, Kaskel F, Warady BA, et al. New equations to estimate GFR in children with CKD. J Am Soc Nephrol 2009;20:629-37. https://doi.org/10.1681/ASN.2008030287
  13. Zappitelli M, Joseph L, Gupta IR, Bell L, Paradis G. Validation of child serum creatinine-based prediction equations for glomerular filtration rate. Pediatr Nephrol 2007;22:272-81.
  14. Ardissino G, Testa S, Dacco V, Vigano S, Taioli E, Claris-Appiani A, et al. Proteinuria as a predictor of disease progression in children with hypodysplastic nephropathy. Data from the Ital Kid Project. Pediatr Nephrol 2004;19:172-7. https://doi.org/10.1007/s00467-003-1268-0
  15. Lane PH. Puberty and chronic kidney disease. Adv Chronic Kidney Dis 2005;12: 372-7. https://doi.org/10.1053/j.ackd.2005.07.009
  16. Kawaguchi H, Hattori M, Ito K. Somatic and renal effects of growth hormone in rats with chronic renal failure. Pediatr Nephrol 1997; 11:280-4. https://doi.org/10.1007/s004670050277
  17. Tonshoff B, Fine RN. Recombinant human growth hormone for children with renal failure. Adv Ren Replace Ther 1996;3:37-47. https://doi.org/10.1016/S1073-4449(96)80039-2
  18. Mehls O, Broyer M. Growth response to recombinant human growth hormone in short prepubertal children with chronic renal failure with or without dialysis. The European/Australian Study Group. Acta Paediatr Suppl 1994;399:81-7.
  19. Soares CM, Diniz JS, Lima EM, Silva JM, Oliveira GR, Canhestro MR, et al. Clinical outcome of children with chronic kidney disease in a pre-dialysis interdisciplinary program. Pediatr Nephrol 2008;23:2039-46. https://doi.org/10.1007/s00467-008-0868-0
  20. Hohenfellner K, Wingen AM, Nauroth O, Wuhl E, Mehls O, Schaefer F. Impact of ACE I/D gene polymorphism on congenital renal malformations. Pediatr Nephrol 2001;16: 356-61. https://doi.org/10.1007/s004670100567
  21. Lee-Chen GJ, Liu KP, Lai YC, Juang HS, Huang SY, Lin CY. Significance of the tissue kallikrein promoter and transforming growth factor-beta1 polymorphisms with renal progression in children with vesicoureteral reflux. Kidney Int 2004;65:1467-72. https://doi.org/10.1111/j.1523-1755.2004.00526.x
  22. Liu KP, Lin CY, Chen, HJ, Wei CF, Lee-Chen GJ. Renin-angiotensin system polymorphisms in Taiwanese primary vesicoureteral reflux. Pediatr Nephrol 2004;19: 594-601. https://doi.org/10.1007/s00467-003-1379-7
  23. Gonzalez CC, Bitsori M, Tullus K. Progression of chronic renal failure in children with dysplastic kidneys. Pediatr Nephrol 2007; 22:1014-20. https://doi.org/10.1007/s00467-007-0459-5
  24. Wong CS, Pierce CB, Cole SR, Warady BA, Mak RH, Benador NM, et al. Association of proteinuria with race, cause of chronic kidney disease, and glomerular filtration rate in the chronic kidney disease in children study. Clin J Am Soc Nephrol 2009;4:812-9. https://doi.org/10.2215/CJN.01780408
  25. Wuehl E, Mehls O, Schaefer F. ESCAPE Trial Group: Long-term dissociation of antiproteinuric and antihypertensive efficacy of ACE inhibition in children with chronic renal failure. COD.OC 16 [Abstract] Pediatr Nephrol 2006;21:1505.
  26. Gouva C, Nikolopoulos P, Ioannidis JP, Siamopoulos KC. Treating anemia early in renal failure patients slows the decline of renal function: a randomized controlled trial. Kidney Int 2004;66:753-60. https://doi.org/10.1111/j.1523-1755.2004.00797.x
  27. Han KH, Lee SH, Lee HK, Choi HJ, Lee BH, Cho HY, et al. Risk factors for the progression of pediatric chronic kidney disease - a single center study. J Korean Soc Pediatr Nephrol 2007;11:239-246. https://doi.org/10.3339/jkspn.2007.11.2.239
  28. Schwarz S, Trivedi BK, Kalantar-Zadeh K, Kovesdy CP. Association of disorders in mineral metabolism with progression of chronic kidney disease. Clin J Am Soc Nephrol 2006;1:825-31. https://doi.org/10.2215/CJN.02101205
  29. Gooch K, Culleton BF, Manns BJ, Zhang J, Alfonso H, Tonelli M, et al. NSAID use and progression of chronic kidney disease. Am J Med 2007;120:270 e1-7.
  30. Klahr S, Levey AS, Beck GJ, Caggiula AW, Hunsicker L, Kusek JW, et al. The effects of dietary protein restriction and bloodpressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group. N Engl J Med 1994;330:877-84. https://doi.org/10.1056/NEJM199403313301301
  31. Chaturvedi S, Jones C. Protein restriction for children with chronic renal failure. Cochrane Database Syst Rev 2007;17:CD006863.
  32. Ardissino G, Vigano S, Testa S, Dacco V, Paglialonga F, Leoni A, et al. No clear evidence of ACEi efficacy on the progression of chronic kidney disease in children with hypodysplastic nephropathy--report from the ItalKid Project database. Nephrol Dial Transplant 2007;22:2525-30. https://doi.org/10.1093/ndt/gfm237
  33. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet 1997; 349:1857-63. https://doi.org/10.1016/S0140-6736(96)11445-8
  34. Litwin M, Grenda R, Sladowska J, Antoniewicz J. Add-on therapy with angiotensin II receptor 1 blocker in children with chronic kidney disease already treated with angiotensin-converting enzyme inhibitors. Pediatr Nephrol 2006;21:1716-22. https://doi.org/10.1007/s00467-006-0223-2
  35. Trachtman H, Christen E, Frank R, Rini J, Palestro C, Perelstein E, et al. Pilot Study of Mycophenolate Mofetil for Treatment of Kidney Disease due to Congenital Urinary Tract Disorders in Children. Am J Kidney Dis 2008;52:706-15. https://doi.org/10.1053/j.ajkd.2008.03.035
  36. Fried LF, Orchard TJ, Kasiske BL. Effect of lipid reduction on the progression of renal disease: a meta-analysis. Kidney Int 2001; 59:260-9. https://doi.org/10.1046/j.1523-1755.2001.00487.x
  37. Perkins RM, Aboudara MC, Uy AL, Olson SW, Cushner HM, Yuan CM. Effect of pentoxifylline on GFR decline in CKD: a pilot, double-blind, randomized, placebo-controlled trial. Am J Kidney Dis 2009;53:606-16. https://doi.org/10.1053/j.ajkd.2008.11.026
  38. Iida S, Kohno K, Yoshimura J, Ueda S, Usui M, Miyazaki H, et al. Carbonic-adsorbent AST-120 reduces overload of indoxyl sulfate and the plasma level of TGF-beta1 in patients with chronic renal failure. Clin Exp Nephrol 2006;10:262-7. https://doi.org/10.1007/s10157-006-0441-8
  39. Levin A. The advantage of a uniform terminology and staging system for chronic kidney disease (CKD). Nephrol Dial Transplant 2003;18:1446-51. https://doi.org/10.1093/ndt/gfg241
  40. Shemin D, Bostom AG, Lambert C, Hill C, Kitsen J, Kliger AS. Residual renal function in a large cohort of peritoneal dialysis patients: change over time, impact on mortality and nutrition. Perit Dial Int 2000;20:439-44.
  41. Guzzo I, Mancini E, Wafo SK, Rava L, Picca S. Residual renal function and nutrition in young patients on chronic hemodialysis. Pediatr Nephrol 2009;24:1391-7. https://doi.org/10.1007/s00467-009-1144-7